Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03021018 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting
A Phase 2 study, sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT03021018 is a Phase 2 study that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 46 participants.
The verdict
NCT03021018, a Phase 2 study, has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV) compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.
Interventions
- DRUG Brivaracetam
- DRUG Lorazepam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-02-06 |
| Est. Completion | 2018-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03021018
The ClinicalTrials.gov registry entry for NCT03021018 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brivaracetam is the first listed.
NCT03021018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03021018 about?
NCT03021018 is a clinical study titled "A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting". The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV) compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.
What is the current status of trial NCT03021018?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2017-02-06. Estimated completion is 2018-04-27.
What interventions are being tested in trial NCT03021018?
The interventions under investigation include: Brivaracetam (DRUG), Lorazepam (DRUG).
Who is sponsoring clinical trial NCT03021018?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.